Survodutide, an investigational glucagon/GLP-1 receptor dual agonist, was noninferior to placebo for major adverse cardiovascular events in adults with overweight or obesity and elevated cardiovascular risk, according to phase 3 SYNCHRONIZE-CVOT results presented Nov. 9 at the American Heart Association (opens in new tab) Scientific Sessions and simultaneously published in The Lancet, AJMC (opens in new tab) reported. Boehringer Ingelheim described the study as the first global cardiovascular safety trial of a glucagon/GLP-1 dual agonist and said it is preparing regulatory submissions for survodutide in obesity, AJMC (opens in new tab) reported. The drug is not approved for any use.

The double-blind, event-driven trial enrolled 5,530 adults with obesity or overweight and established cardiovascular disease, chronic kidney disease, and/or at least two weight-related complications or risk factors, AJMC (opens in new tab) reported. Participants received once-weekly survodutide 3.6 mg, survodutide 6.0 mg, or placebo. The primary end point was time to first five-point MACE — cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, ischemia-related coronary revascularization, or heart failure events — and survodutide was noninferior to placebo (hazard ratio 0.89; 95% CI, 0.67-1.18; P < .001 for noninferiority), AJMC (opens in new tab) reported.

Using a supplementary estimand, systolic blood pressure decreased by up to 6.68 mm Hg with survodutide versus 1.76 mm Hg with placebo at 72 weeks, waist circumference decreased by up to 11.96 cm versus 2.74 cm, and body weight fell by up to 13.7% versus 2.0% in a population that included people with type 2 diabetes, AJMC (opens in new tab) reported. Gastrointestinal events were the most common adverse events. Discontinuation because of gastrointestinal adverse events occurred in 19.3% of participants on 3.6 mg and 20.8% on 6.0 mg, versus 1.9% with placebo, AJMC (opens in new tab) said.

"The SYNCHRONIZE-CVOT trial findings represent an important milestone for survodutide clinical development, as this is the first time we have demonstrated survodutide safety with respect to major adverse cardiovascular events," Shashank Deshpande, chairman of Boehringer Ingelheim's board of managing directors, said in a statement quoted by AJMC (opens in new tab). Neerja Balachander, who oversees clinical development medical affairs for cardio-renal-metabolism at Boehringer, told Fierce Biotech (opens in new tab) the company aims to submit an approval application to treat weight loss "at some time in the next year." A June readout from the separate SYNCHRONIZE-1 trial is a different study and is not the basis for this report.